Back to Browse Journals » Vaccine: Development and Therapy » Volume 2

Advances in the development of vaccines for dengue fever

Authors Simmons M, Teneza-Mora N, Putnak R

Published Date May 2012 Volume 2012:2 Pages 1—14


Received 1 March 2012, Accepted 15 March 2012, Published 4 May 2012

Monika Simmons1, Nimfa Teneza-Mora1, Robert Putnak2

1Viral and Rickettsial Diseases Department, Naval Medical Research Center, 2Division of Viral Diseases, Walter Reed Army Institute of Research, Silver Spring, MD, USA

Abstract: Dengue fever is caused by the mosquito-borne dengue virus (DENV) serotypes 1–4, and is the most common arboviral infection of humans in subtropical and tropical regions of the world. There are currently no prophylaxis or treatment options in the form of vaccines or antivirals, leaving vector control the only method of prevention. A particular challenge with DENV is that a successful vaccine has to be effective against all four serotypes without predisposing for antibody-mediated enhanced disease. In this review, we discuss the current lead vaccine candidates in clinical trials, as well as some second-generation vaccine candidates undergoing preclinical evaluation. In addition, we discuss DENV epidemiology, clinical disease and strategies used for Flavivirus antivirals in the past, the development of new DENV therapeutics, and their potential usefulness for prophylaxis and treatment.

Keywords: tetravalent dengue vaccine, live attenuated vaccine, purified inactivated vaccine, DNA vaccine, antibody-dependent enhancement, antivirals

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Dengue viruses exhibit strain-specific infectivity and entry requirements in vitro

Barr KL, Anderson BD

Virus Adaptation and Treatment 2013, 5:1-9

Published Date: 12 April 2013

Realizing the promise of breast cancer vaccines

Jackson E, Soliman H

Vaccine: Development and Therapy 2012, 2:35-41

Published Date: 22 August 2012

Reasons for not having received influenza vaccination and its predictors in Canadians

Chen Y, Wu J, Yi QL, Laroche J, Wong T

Vaccine: Development and Therapy 2012, 2:23-33

Published Date: 13 August 2012

Treatment of dengue fever

Rajapakse S, Rodrigo C, Rajapakse A

Infection and Drug Resistance 2012, 5:103-112

Published Date: 23 July 2012

Appropriate statistical testing of quality of life scores from children with asthma and their caregivers

Myers JA, Steiner RWP, Legleiter J, Chen YT, Esterhay RJ

Open Access Medical Statistics 2012, 2:15-20

Published Date: 20 February 2012

The utility of human challenge studies in vaccine development: lessons learned from cholera

Shirley DT, McArthur MA

Vaccine: Development and Therapy 2011, 1:3-13

Published Date: 5 October 2011

A new forum to spread the word on vaccine research

Pasetti MF

Vaccine: Development and Therapy 2011, 1:1-2

Published Date: 2 May 2011

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008